secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0001193125-24-279038
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon positive real-world evidence study of ANX005 in Guillain-Barré Syndrome shows benefit over IVIg/PE
--------------------------------------------------------------------------------

- ANX005 30 mg/kg showed faster improvement in muscle strength vs matched IVIg/PE cohort at week 1 (p<0.0001).
- Patients on ANX005 ~2x more likely to be in better health on GBS-Disability Scale at week 8 (p=0.0459).
- Fewer ANX005 patients required mechanical ventilation (15/79 vs 32/79, p=0.022); 12 fewer median days on ventilation and in ICU.
- Planned U.S. Biologics License Application submission for ANX005 in GBS in first half 2025.
- Study used propensity-score matching between Phase 3 patients (n=79) and IGOS global registry patients (n=79).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524279038/0001193125-24-279038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524279038/d909577d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-279038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer